Opthea Completes COAST Final Week 52 Patient Visit
Posted: 19 February 2025 Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it has completed the…
Navi Medical Technologies secures FDA Clearance
Posted: 17 February 2025 Breakthrough Victoria portfolio company, Navi Medical Technologies (Navi), has taken a major step in their mission to making hospital care safer for newborn babies and children, receiving FDA clearance for their Neonav® ECG Tip…
Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for bone repair
Posted: 17 February 2025 Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates and screws typically used to hold fractured bones together. Surgeons…
Breakthrough IBD treatment heads into clinical trials
Posted: 17 February 2025 People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most difficult to treat conditions associated with the disease. IBD is the collective term…
Groundbreaking Research Sheds Light on Cerebellar Ataxias: Advancing Hope for Balance Disorder Treatment
Posted: 17 February 2025 At the Bionics Institute, we are committed to pushing the boundaries of medical research to address the most pressing and overlooked health challenges. One such challenge are the cerebellar ataxias, a devastating group of…
How advanced drug discovery tech is fast-tracking new treatments
Posted: 17 February 2025 On the same day that the National Drug Discovery Centre was officially launched at WEHI, the World Health Organization declared COVID-19 a pandemic. Within weeks, the NDDC had tested over 400,000 compounds to find starting points…
Illuccix Approved in the United Kingdom
Posted: 14 February 2025 Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of…
New research assists understanding of immune response to cancers, chronic disease
Posted: 13 February 2025 A discovery about the mechanisms that enable the immune system to sustain long-term protection could revolutionise treatment for chronic disease and cancer. Prolonged illnesses like cancer and chronic infections often leave the immune system…
New “all-tablet” treatment advance for common form of leukaemia
Posted: 10 February 2025 An international study published today in the New England Journal of Medicine provides hope for chronic lymphocytic leukaemia (CLL) patients with a new all-tablet treatment showing impressive results. The AMPLIFY clinical trial included over 800 never-before-treated…
Type C Meeting granted by FDA for Phelan-McDermid syndrome
Posted: 10 February 2025 Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted a Type C Meeting to discuss the primary efficacy endpoints in Neuren’s planned pivotal Phase 3 clinical trial…
High resolution retinal maps aid disease diagnoses
Posted: 6 February 2025 Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes, dementia and multiple sclerosis.…
Cell Bauhaus receives $3 million grant for digital twin research into cell behaviour
Posted: 6 February 2025 University of Melbourne affiliated startup Cell Bauhaus has received a $3 million grant from the Gates Foundation (formerly the Bill & Melinda Gates Foundation) to continue their work utilising digital twins to investigate how…
